Mark S. Walker

3.1k total citations
121 papers, 2.1k citations indexed

About

Mark S. Walker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mark S. Walker has authored 121 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Mark S. Walker's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Treatment and Pharmacology (20 papers) and Advanced Breast Cancer Therapies (12 papers). Mark S. Walker is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Treatment and Pharmacology (20 papers) and Advanced Breast Cancer Therapies (12 papers). Mark S. Walker collaborates with scholars based in United States, United Kingdom and Japan. Mark S. Walker's co-authors include Lee S. Schwartzberg, Edwin B. Fisher, Edward J. Stepanski, Arthur C. Houts, Paul J. Miller, Randy J. Larsen, Ramaswamy Govindan, Bruce H. Haughey, Stephen L. Ristvedt and L. Johnetta Blakely and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark S. Walker

114 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark S. Walker United States	26	855	572	462	231	207	121	2.1k
David Wyld Australia	24	1.2k 1.4×	423 0.7×	225 0.5×	154 0.7×	201 1.0×	127	2.1k
Simon J. Hall United States	29	873 1.0×	970 1.7×	511 1.1×	125 0.5×	522 2.5×	88	2.9k
Anne Tang United States	24	1.2k 1.4×	451 0.8×	1.0k 2.2×	215 0.9×	272 1.3×	54	3.1k
Richard R. Reich United States	25	1.1k 1.3×	599 1.0×	174 0.4×	418 1.8×	285 1.4×	88	2.9k
Pauline A. J. Vissers Netherlands	23	722 0.8×	306 0.5×	221 0.5×	125 0.5×	284 1.4×	88	1.4k
Mariusz Chabowski Poland	25	885 1.0×	844 1.5×	179 0.4×	255 1.1×	285 1.4×	146	2.1k
Lothar Häberle Germany	28	529 0.6×	381 0.7×	274 0.6×	178 0.8×	251 1.2×	105	2.3k
Thomas Cerny Switzerland	25	921 1.1×	477 0.8×	568 1.2×	229 1.0×	218 1.1×	53	2.2k
Joseph A. Lucci United States	27	968 1.1×	381 0.7×	348 0.8×	130 0.6×	415 2.0×	89	2.7k
Karleen Schulze Canada	25	782 0.9×	705 1.2×	150 0.3×	235 1.0×	530 2.6×	49	2.6k

Countries citing papers authored by Mark S. Walker

Since Specialization

Citations

This map shows the geographic impact of Mark S. Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Walker more than expected).

Fields of papers citing papers by Mark S. Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Walker. The network helps show where Mark S. Walker may publish in the future.

Co-authorship network of co-authors of Mark S. Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Walker. A scholar is included among the top collaborators of Mark S. Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Walker. Mark S. Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ray, Herman E., et al.. (2024). Comparing prospectively assigned trial and real-world lung cancer patients. Journal of Comparative Effectiveness Research. 13(7). e230176–e230176. 3 indexed citations

Fisher, Maxine D., et al.. (2023). Real-World Outcomes in Metastatic HR+/HER2-, HER2+ and Triple Negative Breast Cancer after Start of First-Line Therapy. Future Oncology. 19(13). 909–923. 3 indexed citations

Hu, Xin, Cameron M. Kaplan, Michelle Y. Martin, et al.. (2022). Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 32(2). 167–174. 6 indexed citations

Walker, Mark S., et al.. (2020). PCN284 PERFORMANCE OF TIME TO DISCONTINUATION AND TIME TO NEXT TREATMENT AS PROXY MEASURES COMPARED WITH DIRECT OBSERVATION OF PROGRESSION-FREE SURVIVAL. Value in Health. 23. S73–S73. 1 indexed citations

Kushi, Lawrence H., Andrew J. Belli, Marley Boyd, et al.. (2020). Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.. Journal of Clinical Oncology. 38(15_suppl). e19311–e19311. 1 indexed citations

Houts, Arthur C., et al.. (2019). Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings. Cancer Treatment and Research Communications. 19. 100121–100121. 17 indexed citations

Olufade, Temitope, et al.. (2019). Real‐world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer. The Breast Journal. 26(2). 112–119. 4 indexed citations

Campbell, Matthew D., Mark S. Walker, Ramzi Ajjan, et al.. (2017). An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial. Diabetes and Vascular Disease Research. 14(4). 336–344. 19 indexed citations

Houts, Arthur C., Sarika Ogale, S. Yousuf Zafar, et al.. (2017). Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. Journal of Gastrointestinal Cancer. 50(1). 16–22. 5 indexed citations

10.

Walker, Mark S.. (2015). The Function of TAR1 and the Evolution of the Retrograde Response. University of Canterbury Research Repository (University of Canterbury).

11.

Houts, Arthur C., Mark S. Walker, Leonardo Nicacio, et al.. (2014). Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel. The Journal of Community and Supportive Oncology. 12(9). 321–328. 4 indexed citations

12.

Hirsch, Bradford R., Michael R. Harrison, Daniel J. George, et al.. (2014). Use of “Real-World” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Medical Oncology. 31(9). 156–156. 7 indexed citations

13.

Schwartzberg, Lee S., Grace Wang, Bradley G. Somer, et al.. (2013). Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 14(1). 13–19. 42 indexed citations

14.

Miller, Paul J., Sanjeev Balu, Deborah Buchner, et al.. (2013). Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer. Journal of Medical Economics. 16(10). 1179–1189. 12 indexed citations

15.

Tillmanns, Todd, M. Patrick Lowe, Mark S. Walker, Edward J. Stepanski, & Lee S. Schwartzberg. (2012). Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecologic Oncology. 128(2). 221–228. 40 indexed citations

16.

Hayes, Louise, Mark S. Pearce, Michael Firbank, et al.. (2010). Do obese but metabolically normal women differ in intra-abdominal fat and physical activity levels from those with the expected metabolic abnormalities? A cross-sectional study. BMC Public Health. 10(1). 723–723. 40 indexed citations

17.

Walker, Mark S., Lee S. Schwartzberg, Edward J. Stepanski, & Barry Fortner. (2009). A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Research and Treatment. 115(2). 415–422. 13 indexed citations

18.

Schootman, Mario, Mark S. Walker, Donna B. Jeffe, James E. Rohrer, & Elizabeth A. Baker. (2007). Breast Cancer Screening and Incidence in Communities With a High Proportion of Uninsured. American Journal of Preventive Medicine. 33(5). 379–386.e2. 25 indexed citations

19.

Zeggini, Eleftheria, W Rayner, Andrew P. Morris, et al.. (2005). An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data sets. Nature Genetics. 37(12). 1320–1322. 79 indexed citations

20.

Walker, Mark S., et al.. (2004). Video preparation for breast cancer treatment planning: Results of a randomized clinical trial. Psycho-Oncology. 14(5). 408–420. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact